Viacell, Inc.
Records under this name other than the patents Viacell, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,759,315 | Methods for rejuvenating Lapsed on the fee record Ended Jun 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 24, 2026 | From the USPTO record |
| US 8,613,906 | Treatment of ischemia using stem cells Formerly held Lapsed on the fee record Ended Dec 24, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 24, 2025 | From the USPTO record |
| US 7,452,529 | Treatment of muscular dystrophy with cord blood cells Formerly held Term ended Term ended Jul 23, 2022 · From the USPTO record | Term ended | Term ended Jul 23, 2022 | From the USPTO record |
| US 7,811,557 | Methods for improving central nervous system functioning Formerly held Term ended Term ended May 11, 2022 · From the USPTO record | Term ended | Term ended May 11, 2022 | From the USPTO record |
| US 7,687,468 | Rejuvenation of stored blood Lapsed on the fee record Ended Mar 30, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 30, 2022 | From the USPTO record |
| US 7,560,280 | Human cord blood derived unrestricted somatic stem cells (USSC) Formerly held Lapsed on the fee record Ended Jul 14, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jul 14, 2021 | From the USPTO record |
| US 7,556,801 | Human cord blood derived unrestricted somatic stem cells (USSC) Formerly held Lapsed on the fee record Ended Jul 7, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jul 7, 2021 | From the USPTO record |
| US 6,866,843 | Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell Term ended Term ended May 23, 2021 · From the USPTO record | Term ended | Term ended May 23, 2021 | From the USPTO record |
| US 8,337,833 | Methods of improving central nervous system functioning Term ended Term ended Oct 27, 2020 · From the USPTO record | Term ended | Term ended Oct 27, 2020 | From the USPTO record |
| US 6,429,012 | Cell population containing non-fetal hemangioblasts and method for producing same Formerly held Term ended Term ended Oct 6, 2017 · From the USPTO record | Term ended | Term ended Oct 6, 2017 | From the USPTO record |